Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial

Verstovsek, S.; Vannucchi, A.; Griesshammer, M.; Masszi, T.; Durrant, S.; Passamonti, F.; Harrison, C.; Pane, F.; Zachée, P.; Kirito, K.; Besses, C.; Hino, M.; Moiraghi, B.; B. Miller, Carole; Cazzola, M.; Rosti, V.; Blau, I.; Mesa, R.; M. Jones, Mark; Zhen, H.; Li, Jingjin; Francillard, Nathalie; Habr, D.; Kiladjian, J.

doi:10.3324/haematol.2016.143644

Public

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial

Shared by NobleBlocks on Jul 1, 2016 • 12:00 AM UTC

Authors:

S. Verstovsek

A. Vannucchi

M. Griesshammer

Abstract

RESPONSE is an open-label phase 3 study evaluating the Janus kinase 1/Janus kinase 2 inhibitor ruxolitinib versus best available therapy for efficacy/safety in hydroxyurea-resistant or intolerant patients with polycythemia vera. This preplanned analysis occurred when all patients completed the Week ...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!